Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
Patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome
(MDS) will receive lymphodepleting chemotherapy (Flu/Cy) and two infusions of
cytokine-induced memory-like NK cells at the previously defined maximum tolerated dose (MTD),
fourteen days apart. Low dose rhIL-2 will be administered to patients for in vivo expansion
following cell infusion. Patients will be assessed for anti-leukemic efficacy and safety.
Re-infusion of patients who relapsed after clinical response will be considered.